Review

Delivery of RNAs to Specific Organs by Lipid Nanoparticles for Gene Therapy

Kelly Godbout 1,2 and Jacques P. Tremblay 1,2,*

1 Centre de Recherche du CHU de Québec, Laval University, Québec, QC G1V 4G2, Canada
2 Department of Molecular Medicine, Faculty of Medicine, Laval University, Québec, QC G1V 0A6, Canada
* Correspondence: jacques-p.tremblay@crchul.ulaval.ca

Abstract: Gene therapy holds great promise in the treatment of genetic diseases. It is now possible to make DNA modifications using the CRISPR system. However, a major problem remains: the delivery of these CRISPR-derived technologies to specific organs. Lipid nanoparticles (LNPs) have emerged as a very promising delivery method. However, when delivering LNPs intravenously, most of the cargo is trapped by the liver. Alternatively, injecting them directly into organs, such as the brain, requires more invasive procedures. Therefore, developing more specific LNPs is crucial for their future clinical use. Modifying the composition of the lipids in the LNPs allows more specific deliveries of the LNPs to some organs. In this review, we have identified the most effective compositions and proportions of lipids for LNPs to target specific organs, such as the brain, lungs, muscles, heart, liver, spleen, and bones.

Keywords: lipid nanoparticles; gene therapy; mRNA delivery; CRISPR/Cas9 delivery; specific organ delivery

1. Introduction

Over the last few years, the enthusiasm for gene therapy [1] has brought out the best in science. Whether through the CRISPR system [2–6] or through RNAs [7], DNA modifications have now become possible and hold great promise. However, a critical question remains unsolved—how to deliver these technologies to specific organs. Several delivery methods have been attempted, such as adeno-associated viruses (AAVs) [8–10], extracellular vesicles (EVs) [11,12], lipid nanoparticles (LNPs) [13–19], etc. Since they were used in Pfizer and Moderna’s COVID-19 vaccines, LNPs are in the spotlight as their safety and effectiveness have been widely proven [20,21]. Furthermore, one of the great advantages of LNPs is their large capacity. They can package large components such as long RNAs and large proteins [22]. This has paved the way for the delivery of the CRISPR technology. This is where LNPs have taken the lead over AAVs, as the capacity of AAVs is at most 5 kb [23]. Regardless of the delivery method, one problem is still present. When delivered intravenously (IV), most of the LNPs are taken up by the liver [24]. Moreover, injecting them directly into an organ, such as the brain, requires invasive techniques [25]. Therefore, modifications of the composition of LNPs to make them more specific are needed. In order to be optimal and functional, LNPs must contain certain classes of lipids.

LNPs are generally composed of four categories of lipids: ionizable cationic lipids, helper lipids (phospholipids), cholesterol, and polyethylene glycol (PEG) lipids (Figure 1) [26–29]. Each of these lipids plays an important role [24,30]. Ionizable cationic lipids have a positive charge that allows them to interact with nucleic acids (which are negatively charged) [31]. When included in LNPs, these lipids allow nucleic acids to be loaded into the particles. A crucial feature of these lipids is that they become protonated at acidic pH. When they become positively charged, the membrane of the particle is destabilized. This allows the LNPs to escape from the endosomes and release their cargo into the cytosol of the cells [32].
These lipids also enhance the efficiency of endocytosis by target cells. Helper lipids are mostly phospholipids. They improve the stability of the nanoparticle [33]. They also increase the efficiency of the delivery [34]. Cholesterol is an essential lipid to include in LNPs. It fills the gaps between the phospholipids, and this increases the stability of the particles [27,34]. PEG lipids constitute the last classical part added to the LNP formulation. These lipids greatly increase the circulation time of LNPs in the body [27,35]. They also decrease immunogenicity [36].

Figure 1. Key components of lipid nanoparticles (LNPs). LNPs are mainly composed of ionizable cationic lipids, helper lipids, cholesterol, and polyethylene glycol (PEG) lipids. Image created with BioRender.com.

By manipulating the composition of lipids (Figure 2) and their proportion in LNPs, it is possible to change their size and surface characteristics. Indeed, the size and charge of LNPs seem to have significant effects on their biodistribution. Therefore, the delivery of the LNPs can be more specific to certain organs. Unfortunately, we still do not clearly understand the precise mechanism that explains the relationship between the biodistribution of LNPs and their size, charge, and the types of lipids used. It would therefore be interesting to conduct fundamental research on this mechanism. Although the explanation behind the biodistribution of some LNPs is not fully understood, the scientific literature is replete with several formulations of LNPs having the ability to target a specific organ. In this review, we have identified the most effective formulations of lipid nanoparticles for passive targeting of specific organs, such as muscles, brain, lungs, liver, heart, spleen, and bones. Active targeting is another strategy to target specific organs, but it will not be discussed in this review. For more information on this strategy, Menon et al. [37] have published an article on this subject. As passive targeting with lipid nanoparticles is a vast subject in itself, in this review we will discuss the types of lipids to use, as well as their proportions, in order to deliver gene therapies to specific organs, especially extrahepatic ones.
Pharmaceutics 2022, 14, x FOR PEER REVIEW 4 of 21

Figure 2. Chemical structures of some lipids used in LNPs. LNPs are generally composed of four categories of lipids: ionizable cationic lipids, helper lipids (phospholipids), cholesterol, and PEG lipids. A permanently charged cationic lipid can sometimes be added. TCL053, C12-200, YSK05, 5A2-SC8, DLin-K2-DMA, 9A1P9, DLin-MC3-DMA, and 306-O12B-3 are the principal ionizable cationic lipids used. DPPC, DOPE, and DSPC are the main helper lipids used. DMG-PEG and DSPE-PEG are the most used PEG lipids. There are three kinds of permanently charged cationic lipids that are mainly used: DOTAP, DOTMA, and 18PA. Image created with BioRender.com. The figure was adapted from [38–54].

2. Targeting the Muscles

Myopathies (e.g., Duchenne’s muscular dystrophy (DMD) [55,56], Steinert’s myopathy [57], diseases related to a mutation in the RYR1 gene [58], and many others [59]) greatly affect the quality of life and the life expectancy of many patients. To eventually treat these patients, many researchers have developed drugs [60] or used gene therapy [61,62]. However, it is still very difficult to deliver the therapy specifically to the muscles of the whole body.

Different routes have been used in attempts to target the muscles (Table 1). Intramuscular injections have been attempted [63–66]. Some researchers have also tried to reach the muscles via intravenous [63,67,68] or intraperitoneal injection [69].

Only a few studies have succeeded in targeting muscles through intravenous injections of LNPs. The major problem with this route is that LNPs are taken up by the liver and the spleen [70]. Kenjo et al. [63] delivered CRISPR-Cas9 mRNA with a sgRNA targeting the DMD gene by injecting LNPs in the dorsal saphenous vein. They used the following composition: TCL053/DPPC/cholesterol/DMG-PEG (60:10.6:27.3:2.1). The lipid/RNA weight ratio was 23:1. The size of these LNPs was 79.1 nm. When the injection volume of the limb perfusion was greater than 5 mL/kg, they succeeded in editing the target gene in various limb muscles. However, it is important to note that they used a tourniquet at the bottom of the quadriceps. This method allows the LNPs to remain concentrated around the muscles under the tourniquet without traveling to the liver or other organs. However,
tourniquets can be used for the legs and the arms but are useless for the other muscles of the body, such as the diaphragm.

Table 1. LNP formulations targeting muscles in vivo.

| Reference | Delivered Cargo | Targeted Tissue/Gene | Route | No. of Doses | Dose | LNP Formulation | Lipid: RNA (or DNA) Ratio (w:w) | Results |
|-----------|-----------------|----------------------|-------|-------------|------|----------------|-------------------------------|---------|
| Kenjo 2021 [63] | CRISPR-Cas9 mRNA/sgRNA | Muscles/DMD | IM | 1 | 1 mg/kg sgRNA | 5A2-SC8 | 21.4 | Restoration of dystrophin |
| Wei 2020 [66] | RNP | Muscles/DMD | IM | 1 | 1 mg/kg sgRNA | DOPE, Cholesterol | 21.4, 42.8 | td-Tom fluorescence near the injection site |
| Guimaraes 2019 [67] | b-mRNA | Muscles | IV | 1 | 0.25 µg de b-mRNA | DOPE, Cholesterol | 21.4, 42.8 | 7.5:1 |
| Carrasco 2021 [65] | FLuc mRNA | Muscles | IM | 5 µg | DMG-PEG | 2.5 | 4.2% restoration of dystrophin |
| Blakney 2019 [64] | FLuc saRNA | Muscles | IM | 5 µg | C12-200, DOPE, Cholesterol | 35, 16 | 12:1 |

1 Ionizable lipid:RNA ratio.

5A2-SC8 = C₉₃H₁₇₃N₅O₂₅S₅; ASO = antisense oligonucleotide; C12-200 = 1,1′-[[2-[4-[2-[[2-[bis(2-hydroxydodecyl) amino]ethyl][2-hydroxydodecyl]amino]ethyl]-1-piperazinyl]ethyl]lmino]bis-2-dodecanol; DLin-KC2-DMA = 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane; DMD = dystrophin gene; DOPE = 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; DOTAP = 1,2-dioleoyl-3-trimethylammonium-propane; DPPC = distearoylphosphatidylcholine; FLuc = firefly luciferase; IM = intramuscular; IP = intraperitoneal; IV = intravenous; PEG3000-C16 = 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-3000]; DMG-PEG = 1,2-Dimyristoyl-rac-glycero-3-methoxy(polyethylene glycol)-2000; RNP = Ribonucleoproteins; TCL053 = 2-(((4-(dimethylamino)butanoyl)oxy)methyl)-2-(((Z)-tetrade-9-enoyl)oxy)methyl)propane-1,3-diyl (9Z,9’Z)-bis(tetradec-9-enoate); w:w = weight:weight.

Kenjo et al. [63] also tried the same lipid composition that was used intravenously for intramuscular injection in the tibialis anterior (TA) muscle of a mouse model of Duchenne muscular dystrophy (DMD). After six injections, dystrophin expression was restored in 38.5% of muscle fibers. In each injection, the authors used 10 µg of Cas9 mRNA with 10 µg of sgRNA targeting the DMD gene to provide exon skipping. As six is a high number of injections, some modifications should be identified to increase the method’s efficiency at a lower number of injections. For comparison, after three injections, they obtained only about 15% exon skipping and around 4.0% dystrophin recovery.

Wei et al. [66] used an interesting composition, with which they succeeded in encapsulating ribonucleoprotein complexes (RNPs, i.e., Cas9 proteins and sgRNAs) and delivering...
them to the muscle via intramuscular injections. RNPs are interesting because the Cas9 nuclease does not need to be translated since the protein is already there. Compared to Cas9 mRNA delivery, direct delivery of the Cas9 protein makes editing much faster and more direct. This strategy has also been shown to decrease the risk of off-target effects [71]. By avoiding a sustained expression of Cas9, this strategy has low immunogenicity [72–79].

However, the delivery of the Cas9 protein is much more challenging than the delivery of its mRNA. The large size of this protein makes it more difficult to encapsulate. It is also more complicated to avoid degradation or denaturation of the protein during the assembly of the LNPs and the delivery process. Since sgRNAs have a highly negative charge, they are more difficult to encapsulate in LNPs [24].

Some lipid compositions of LNPs are therefore more useful for delivering RNPs. By adding a permanently charged cationic lipid, such as DOTAP, to a conventional LNP composition, Wei et al. [66] were able to preserve the integrity of the RNPs and deliver them to their destinations.

The molar ratio of Cas9/sgRNA used was 3/1. The sgRNA was targeting the DMD gene. Their LNPs were composed of 5A2-SC8/DOPE/cholesterol/DMG-PEG/DOTAP = 21.4/21.4/42.8/4.3/10 (mol/mol) and their lipid/RNA ratio was 40:1 (w:w) [66]. Their composition was innovative because it included, in addition to the four usual lipids, DOTAP, which is a permanently charged cationic lipid. They found that when using a ratio of 10% of DOTAP, the composition was more specific for muscles. After three injections, they obtained a 4.2% restoration of dystrophin [66]. They also demonstrated that adjusting the concentration of DOTAP changed the specificity of LNPs and targeted different organs (see sections on other organs).

Carrasco et al. [65] delivered LNPs containing FLuc mRNA via intramuscular injections. Their LNPs were composed of DLin-KC2-DMA/DSPC/cholesterol/DMG-PEG (50/10/38.5/1.5), with a 4:1 mole/mole ratio of ionizable lipid:mRNA. Their results indicated that the LNPs reached the entire leg of the mouse, as well as (to a lower extent) the liver. However, they did not present quantitative results. It would therefore be interesting to test their composition with Cas9 mRNA and an sgRNA targeting the DMD gene, and to determine the percentage of editing in all the different muscles of the leg.

Guimaraes et al. [67] created a library of LNPs containing custom-designed barcoded mRNAs (b-mRNAs). They injected these LNPs into mice intravenously. Using this approach, they identified LNP formulations that could be used to target specific organs. Among the studied LNP compositions, two of them stood out as being effectively delivered to the muscles (the formulations were named F11 and F12). Their composition was as follows: C12-200/DOPE/cholesterol/DMG-PEG with a ratio of 35/16/46.5/2.5. F11 and F12 differed only in terms of their ionizable lipid:mRNA ratios, and therefore their size. F11 had a ratio of 5:1 and a size of 83.55 nm and F12 had a ratio of 7.5:1 and a size of 88.09 nm [67]. Since we do not have the raw data on the number of reads per organ for each LNP, we cannot conclude anything about the specificity of these LNPs. Their specificity would therefore be interesting to evaluate. However, we do know that these LNPs can efficiently reach the muscles following an intravenous injection, which is very relevant to the goal of reaching all the muscles of the body.

Based on all these articles, it is clear that the muscles remain very difficult to reach via IV methods without the LNPs also becoming trapped by other tissues. However, some points stand out when comparing all of these studies. The only one that has so far succeeded in delivering CRISPR-Cas9 mRNA and a sgRNA into muscle intravenously is that of Kenjo et al. [63]. However, they used tourniquets on the mouse legs, which is not realistic to use in humans for all muscles. Therefore, to target all muscles intravenously, it would be interesting to experiment with the encapsulation of CRISPR-Cas9 (mRNA or RNP) with an sgRNA in one of the LNPs described by Guimaraes [67]. It should be noted that in both studies, the ionizable cationic lipid was C12-200. This suggests that this ionizable cationic lipid may increase the specificity of LNPs for the muscles.
3. Targeting the Brain

The brain is the center of many diseases that are still not curable. Alzheimer’s disease [80], Huntington’s chorea [81], epilepsy [82], and brain cancer [83] are just some examples of brain diseases. It is becoming urgent to find a safe and effective method to deliver treatments to the brain.

The brain is very hard to target. It is protected by the skull and the blood–brain barrier (BBB) [84–86], which is very selective for brain penetration. Some investigators have used drastic methods such as intracranial injections [87]. However, this procedure involves huge risks and is very invasive. Since we aimed to identify a minimally invasive and safe delivery method, we discuss the experiments that have reached the brain via intravenous injections in greater detail (Table 2).

| Reference | Delivered Cargo | Targeted Tissue/Gene | Route | No. of Doses | Dose | LNP Formulation | Lipid:RNA (or DNA) Ratio | Results |
|-----------|-----------------|----------------------|-------|-------------|------|-----------------|--------------------------|---------|
| Ma 2020 [88] | ASO targeting tau mRNA | Brain/tau | IV | 5 | 1 mg/kg | 306-O12B-3, DSPE-PEG, NT1-O14B | 67.2 (w) : 4 (w) | ~50% reduction of tau mRNA and ~30% reduction of tau protein |
| Wei 2020 [66] | RNP | Brain | IC | 1 | 0.15 mg/kg sgRNA | 52A-SC8, DOPE, Cholesterol, DMG-PEG, DOTAP | 21.4 : 21.4 : 42.8 : 4.3 : 10 | Strong tdTomato signals were observed in multiple regions of the brain, including the cerebral cortex, hippocampus, and cerebellum. |
| Nabhan 2016 [89] | mRNA | DRG/FXN | IT | 1 | 0.2 mg/kg | DLin-MC3-DMA, DSPC, Cholesterol, DMG-PEG | 55 : 10 : 32.5 : 2.5 | Robust increase in mFXN levels. LNP-derived human mFXN levels were ~3-fold higher than mouse mFXN in the control group |
| Tamaru 2014 [90] | DNA encoding mCherry | BECs | ICV | 70 | YSK05, Cholesterol, DMG-PEG | 70 : 30 : 3 | 5A2-SC8 = C_{30}H_{77}N_{3}O_{19}S_{2}; ASO = antisense oligonucleotide; BECs = brain endothelial cells; C12-200 = 1,1’-[2-[4-[2-[bis(2-hydroxydodecyl)amino]ethyl]l]-2-hydroxydodecyl]amino]ethyl]-1-piperazinyl]ethyl]limonol]ynthia-2-dodecanol; Cre = Cre recombinase is a tyrosine recombinase enzyme derived from the P1 bacteriophage; DLin-KC2-DMA = 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-1,3-dioxolane; DOPE = 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; DOTAP = 1,2-dioleoyl-3-trimethylammonium-propan-2-yl; DMG-PEG = 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000; RNP = ribonucleoproteins; tau = tubulin-associated unit; w = weight; w:w = weight:weight; YSK05 = 1-methyl-4,4-bis[9Z,12Z]-octadeca-9,12-dien-1-yloxy]piperidine. |

Ma et al. [88] developed a class of neurotransmitter-derived lipidoids (NT-lipidoids). These researchers are innovative because they are among the few who have attempted to add neurotransmitter-derived lipidoids (NT-lipidoids) to prior BBB-impermeable LNPs. With the NT-lipidoids allowing them to cross the BBB, these LNPs have successfully delivered antisense oligonucleotides (ASOs) against tau and the genome-editing fusion protein (-27)GFP-Cre recombinase into the mouse brain via systemic intravenous administration. To deliver ASOs against tau, they used the following composition: 306-O12B-3/DSPE-PEG/NT1-O14B with a respective ratio of 67.2/4/28.8 (w:w). They had a total lipid:ASO ratio of 15:1. This led to an approximately 50% reduction in tau mRNA and an approximately 30% reduction in tau protein. Here, the tail vein intravenous method was even more efficient than the implanted ICV pump. To deliver the genome-editing fusion protein (-27)GFP-Cre recombinase, they injected into Ai14 mice the following formulation:
PBA-Q76-O16B/DSPE-PEG/NT1-O14B with a respective ratio of 67.2/4/28.8 (w/w). This experiment was also successful. They observed strong tdTomato signals in multiple regions of the brain, including the cerebral cortex, hippocampus, and cerebellum. These results are therefore very encouraging. It would, however, be interesting to test the specificity of these LNPs to check that they do not travel to the liver or other organs.

Nabhan et al. [89] did not directly target the brain but rather the DRG (dorsal root ganglia). They intrathecally injected LNPs containing the mRNA of the human FXN gene into BALB/c mice to perform RNA transcript therapy (RTT). The composition of their LNPs was as follows: DLin-MC3-DMA/DSPC/cholesterol/DMG-PEG, with a respective ratio of 55/10/32.5/2.5 and a lipid/mRNA weight ratio of 30:1 (w:w). Their LNPs had a size of 85 nm. Their results revealed that human mRNA FXN levels in the DRG were about three-fold higher than mouse mRNA FXN in the control group. Thus, they were able to observe an increase in the level of frataxin protein in the DRG.

They also tried to inject these LNPs into CD1-mice via IV [89]. However, these LNPs were significantly taken up by the liver, but not by the heart and brain, which are the organs affected by ataxia. Fortunately, the additional amount of mFXN in the liver did not adversely influence other mitochondrial proteins.

Therefore, for treatments for ataxia or other diseases affecting the DRG, it would be better to inject the LNPs described above intrathecally [89]. If the brain is to be targeted, it would be judicious to try the formulations described above by Ma et al. [88].

4. Targeting the Lungs

The lungs are the site of devastating diseases. Cystic fibrosis [91,92] and lung cancer [93] come to mind. Fortunately, the delivery of drugs to the lungs is one of the most studied topics in this field (Table 3). For treatments that must reach the lungs, three routes have been prioritized: intravenous, intranasal, and inhalation.

Cheng et al. [94] developed a selective organ targeting (SORT) strategy. They found that the addition of a SORT molecule, 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), to the LNPs permitted them to target an organ specifically. These LNPs are also interesting because they allowed one to deliver multiple gene editing technologies, including mRNA, Cas9 mRNA/single-guide RNA, and Cas9 ribonucleoprotein complexes. To target the lungs, they found that the best LNP had 50% of DOTAP. It had the following formulation: 5A2-SC8/DOPE/Chol/DMG-PEG/DOTAP (11.9/11.9/23.8/2.4/50). First, they intravenously injected these LNPs containing Cas9 mRNA/sgRNA in a 4:1 ratio (w:w). The size of these LNPs was 113.1 nm. They succeeded in editing PTEN exclusively in the lungs with 15.1% indels. Secondly, they intravenously injected these LNPs containing the Cas9 protein with an sgRNA in a 2:1 ratio (w:w). They succeeded in editing specifically in the lungs at 5.3%. They also evaluated the off-target effects for PTEN. Fortunately, they did not detect any off-target DNA editing.

Wei et al. [66] succeeded in encapsulating RNPs and delivering them to the lungs via tail vein injection. The mole ratio of Cas9/sgRNA used was 3:1. Their LNPs were composed of 5A2-SC8/DOPE/cholesterol/DMG-PEG/DOTAP at 11.9/11.9/23.8/2.4/50 (mol/mol) and their lipid/RNA ratio was 40:1 (w:w). As Cheng et al. noted, their composition was innovative as it used DOTAP in addition to the four usual lipids. They noted that when using a ratio of 50% DOTAP, the composition was more specific for the lungs. They intravenously injected Td-Tom mice with these LNPs containing the Cas9 protein and six different sgRNAs (sgTOM, sgP53, sgPTEN, sgEm4, sgALK, and sgRB1). They succeeded in editing the TOM gene, detecting bright Td-Tom fluorescence in the lungs after one week. They also succeeded in editing five other genes in the lungs. They observed clear T7EI cleavage bands. P53, PTEN, EM4, ALK, and RB1 had 1.1%, 3.4%, 7.7%, 1.1%, and 7.5% of indels, respectively. Their experiments demonstrated that these LNPs were able to target the lungs specifically and to edit multiple genes in this organ effectively at low doses (0.33 mg/kg for each sgRNA).
### Table 3. LNP formulations targeting the lungs in vivo.

| Reference      | Delivered Cargo   | Targeted Tissue/Gene | Route | No. of Doses | Dose | LNP Formulation | Lipids Molar Ratios | Lipid: RNA (or DNA) Ratio (w:w) | Results                          |
|----------------|-------------------|----------------------|-------|--------------|------|-----------------|---------------------|---------------------------------|---------------------------------|
| Cheng 2020 [94]| Cas9 protein + sgRNA (RNP) | Lungs/PTEN | IV    | 1            | 1.5 mg/kg sgRNA | 5A2-SC8, DOPE | 11.9               | 40:1                             | 5.3% gene editing                |
|                |                   |                      |       |              | 2.5 mg/kg total RNA | DMG-PEG, DOTAP | 2.4               |                                  | 15.1% gene editing               |
| Wei 2020 [66]  | RNP               | Lungs/PTEN           | IV    | 1            | 1.5 mg/kg sgRNA | 5A2-SC8, DOPE | 11.9               | 40:1                             | 13% indel frequency             |
|                |                   |                      |       |              | 0.33 mg/kg each sgRNA | DOPE, Cholesterol | 11.9, 23.8         |                                  | Gene editing: 1.1% (P53); 3.4% (PTEN); 7.7% (EM14); 1.1% (ALK); 7.5% (RB1) |
|                |                   |                      |       |              | 2 mg/kg sgRNA | DMG-PEG, DOTAP | 2.4               |                                  | 16.3% (EM14); 4.5% (ALK)        |
| Robinson 2018  | cmCFTR mRNA       | Lungs/CFTR           | IN    |              | 0.6 mg cmRNA/kg | DLin-MA-C3-DMA, DSPC, Cholesterol, DMG-PEG | 50, 38.5, 1.5 |                                  | Polarization in response to CFTR |
|                | cmFLuc mRNA       |                      |       |              |                  |                  |                                  |                                  |
| Zhang 2020 [96]| FLuc mRNA         | Heart, Spleen, Lung  | IV    |              | 0.5 mg/kg       | FT77 lipids, DOPE, Cholesterol, DMG-PEG | 22.04, 33.06, 0.82 |                                  |                                  |
| Paunovska 2018 |                   | Lung EC              | IV    |              |                  | 7C1, Cholesteryl Stearate, DMG-PEG | 62, 30, 8 |                                  |                                  |
|                |                   | Lung Macs            | IV    |              |                  | 7C1, DOPE, 7B-OH Cholesterol, DMG-PEG | 50, 8, 40, 2 |                                  |                                  |
| Paunovska 2018 |                   | Heart ECs, Lung ECs  |       |              |                  | 104-PEI600, Lipid = C12Epoxy, PEG50-C18 | 62, 5, 33 |                                  |                                  |
|                |                   | Lungs Macs           | IV    |              | 0.75 mg/kg      | 7C1-PEI600, Lipid = C15Epoxy, PEG50-C14 | 62, 5, 33 |                                  |                                  |
|                |                   | Lungs ECs            |       |              |                  | 7C1-PEI600, Lipid = C15Epoxy, DMG-PEG | 62, 6, 32 |                                  |                                  |
### Table 3. Cont.

| Reference       | Delivered Cargo | Targeted Tissue/Gene                          | Route | No. of Doses | Dose      | LNP Formulation | Lipids Molar Ratios | Lipid:RNA (or DNA) Ratio (w:w) | Results                                                                 |
|-----------------|-----------------|-----------------------------------------------|-------|--------------|-----------|-----------------|---------------------|------------------------|------------------------------------------------------------------------|
| Sago 2018 [99]  | two sgRNAs targeting ICAM2 (sgICAM2a/b) | Lung, Spleen, Kidney                          | IV    | 3            | 1.5 mg/kg | 104-PEI600 Lipid = 1,12Epoxy Lipid = C12Epoxy DMG-PEG-C18 | 62                  | 21                      | 17                      | Good for small RNAs but not for mRNAs                                 |
| Qiu 2022 [100]  | Cas9 mRNA + sgRNA | Lungs/LoxP                                     | IV    | 3            | 1.67 mg/kg | 104-PEI600 Lipid = 1,12Epoxy Lipid = C12Epoxy DMG-PEG-C18 | 62                  | 18                      | 20                      | Good for small RNAs but not for mRNAs                                 |
| Liu 2021 [101]  | Cre mRNA        | Lungs                                          | IV    | 3            | 0.75 mg/kg | 104-PEI600 Lipid = 1,12Epoxy Lipid = C12Epoxy DMG-PEG-C18 | 62                  | 18                      | 20                      | Good for small RNAs but not for mRNAs                                 |
| Hagino 2021 [102]| pDNA + PEI      | Lungs                                          | IV    | 3            | 0.75 mg/kg | 104-PEI600 Lipid = 1,12Epoxy Lipid = C12Epoxy DMG-PEG-C18 | 62                  | 18                      | 20                      | Good for small RNAs but not for mRNAs                                 |

1 Active lipidoid:mRNA ratio.

5A2-SC8 = C93H172N4O2S2; ALK = anaplastic lymphoma kinase gene; C12-200 = 1,1′-[2-[4-[2-[bis(2-hydroxydodecyl)amino]ethyl][2-hydroxydodecyl]amino]ethyl]-1-piperazinyl]ethyl];[limino][bis-2-dodecanol; CFTR = cystic fibrosis transmembrane conductance regulator gene; Cre = Cre recombinase is a tyrosine recombinase enzyme derived from the P1 bacteriophage; DDAB = dimethyldioctadecylammonium; DLin-KC2-DMA = 2,2-dilinoleoyl-4-(2-dimethylaminoethoxy)[1,3]-dioxolane; DOPE = 1,2-diOleoyl-sn-glycero-3-phosphoethanolamine; DOTAP = 1,2-dioleyl-3-trimethylammonium-propionate; DSPC = distearoylphosphatidylcholine; ECs = epithelial cells; FLuc = firefly luciferase; GFP = green fluorescent protein; ICAM2 = intercellular adhesion molecule 2 gene; IN = intranasal; IV = intravenous; Macs = macrophages; P53 = tumor protein 53; DMG-PEG1000-C18 = 1,2-distearyl-sn-glycerol-3-phosphoethanolamine-N-methoxy(polyethylene glycol)-1000]; DMG-PEG = 1,2-dimyristoyl-rac-glycerol-3-methoxypolyethylene glycol-2000; PEI = cationic polymer polyethyleneimine; PTEN = phosphatase and tensin homolog; RBP = retinoblastoma 1 gene; RNP = ribonucleoprotein; w:w = weight:weight; YSK05 = 1-methyl-4,4-bis[9Z,12Z]-octadeca-9,12-dien-1-yloxy]piperidine.
Liu et al. [101] also obtained impressive results. They conducted three LNP delivery experiments, each one containing a different package. In the first one, they inserted Cre mRNA into the LNPs and injected them intravenously into Cre-LoxP mouse models. This LNP succeeded in transfecting about 34% of all endothelial cells, ~20% of all epithelial cells, and ~13% of immune cells. Their LNP formulation contained 9A1P9/DDAB/cholesterol/DMG-PEG (46/23/30.7/0.3 molar ratio). Their ionizable lipid:mRNA ratio was 18:1. The particle size was around 150 nm. They used this same LNP formulation to send the Cas9 mRNA and Tom1 sgRNA intravenously. This experiment resulted in specific gene editing of the lungs. In their final experiment, they inserted Cas9 mRNA and a sgRNA for PTEN with these same LNPs. They obtained efficient target gene editing.

Hagino et al. [102] made a unique LNP. They created a double-coated LNP decorated with the GALA peptide. The GALA peptide has a high affinity for the lung endothelium [103] and was therefore used as a ligand to target the lung endothelium. This peptide was also useful as an endosomal escape device. The inner coat (half of the total lipid) was made of DOPE/STR-R8 (9.55/0.45). The outer coat (the other half) was made of DOTMA/YSK05/cholesterol/DMG-PEG/chol-GALA (4/4/2/0.3/0.4). The size of their LNPs was 125-155 nm. Hagino et al. reported that with this double-coated LNP with the GALA peptide, they obtained one of the highest lung selectivity values reported to date. They estimated the amount of luciferase protein in the lung tissues at \( \sim 74 \text{ ng/mg of protein} \). When delivering the pDNA/PEI complex with this LNP, they observed high gene expression in the lungs. It would be interesting to test the encapsulation of the Cas9 mRNA or protein and the sgRNA with this formulation to verify whether the specificity of these LNPs is preserved.

5. Targeting the Liver

Many diseases can affect the liver. Among them, tyrosinemia [104,105] and autoimmune hepatitis [106] are very severe diseases. Fortunately, LNP delivery to the liver is very effective. It is enhanced by the biological effect of apolipoprotein E (ApoE) [107,108]. After LNPs are injected intravenously, ApoE forms a corona around the particles. Since ApoE binds specifically to receptors on hepatocytes, it directs LNPs towards the liver. This explains why LNPs are more easily trapped by the liver [108]. In addition, the liver can be used as a protein factory [109] to treat various rare diseases through gene therapy. As the liver is an excellent therapeutic target, it is important to optimize delivery to this organ.

Patisiran (ONPATTRO™) is the first RNA drug delivered by LNPs that has been approved by the U.S. Food and Drug Administration (FDA) [107]. This LNP is composed of DLin-MC3-DMA/DSPC/cholesterol/DMG-PEG at a molar ratio of 50:10:38.5:1.5 [110]. As it was the first to be approved, this formulation inspired the composition of other LNPs. Table 4 presents some formulations that target the liver.

Liu et al. [22] obtained impressive results. When delivering LNPs with Cas9 mRNA, along with a sgRNA targeting PCSK9, they succeeded in reducing the serum PCSK9 by 80%. They used the following formulation: BAMEA-16B/DOPE/cholesterol/DSPE-PEG (16/4/8/1 w:w). They used a lipid:mRNA ratio of 15:1 (w:w). Their LNP had a size of 230 nm. Fortunately, they observed no signs of inflammation and no obvious hepatocellular injury.
Table 4. LNP formulations targeting the liver in vivo.

| Reference       | Delivered Cargo                  | Targeted Tissue/Gene | Route | No. of Doses | Dose       | LNP Formulation | Lipids Molar Ratios | Lipid:RNA (or DNA) Ratio (w:w) | Results                                      |
|-----------------|----------------------------------|----------------------|-------|--------------|------------|------------------|---------------------|----------------------------------|---------------------------------------------|
| Cheng 2020 [94] | Cas9 mRNA/sgRNA                  | Liver/PTEN           | IV    | 1            | 2.5 mg/kg  | 5A2-SC8         | 19.05               |                                  | 2.7% gene editing                                           |
|                 | Cas9 protein + sgRNA (RNP)       |                      |       | 1            | 1.5 mg/kg sgRNA | DOPE Cholesterol | 19.05               | 38.1                | 40:1                           | 11.6%–13.9% gene editing, 100% reduction in liver and serum Pcsk9 |
|                 | Cas9 mRNA/sgRNA                  | Liver/PCSK9          |       | 3            | 2.5 mg/kg total RNA | DMG-PEG DOTAP | 3.8                 | 20                  |                                | ~60% gene editing, 5.7% gene editing, reduction of PCSK9 in serum and liver tissue |
| Wei 2020 [66]   | RNP                              | Liver/P53, PTEN, RB1 | IV    | 3            | 2.5 mg/kg sgRNA | 5A2-SC8 DOPE Cholesterol | 22.6               | 45.2                | 40:1                           | 8.6% (P53); 7.9% (PTEN); 13.3% (RB1) gene editing |
|                 |                                  | Liver/PCSK9          |       |              |            |                  |                     |                                  |                                              |
| Zhang 2020 [96] | hFVIII mRNA                       | Liver                | IV    |              | 2 mg/kg    | FTT5 lipids DOPE | 22.04               | 33.06               |                                | Restores the hFVIII level up to 90% of normal activity, 60% of gene editing |
|                 | mRNA encoding ABE + sgRNA        | PCSK9                |       |              | 1 mg/kg of total RNA dose | Cholesterol DMG-PEG | 44.08               | 0.82                |                                |                                              |
| Paunovska 2018 [97] | Liver EC                        |                      | IV    |              |            | 7C1 18:1Lyso PC 4B-OH-Cholesterol DMG-PEG | 50              | 10                  | 29                           | 11                                     |
|                 | Liver hepatocyte                 |                      |       |              |            | 7C1 DOPE 7B-OH Cholesterol DMG-PEG | 50              | 8                   | 40                           | 2                                      |
| Cui 2022 [111,112] | FLuc mRNA                       | Liver; iWAT, gWAT    | IV    |              | 0.25 mg/kg | MC3 DSPC Cholesterol DMG-PEG | 50              | 10                  | 38.5                          | 20:1                                    |
| Rothgangl 2021 [113] | ABE + gRNA                     | Liver/PCSK9          | IV    | 1            | 1.0, 1.5, or 3.0 mg/kg total RNA | Patent: US 2016/0376224 A1 | 50 | 10 | 38.5 | 20:1 | In mice: 4%, 12%, or 51% base editing |
|                 |                                  |                      |       | 2            | 1.5 or 3.0 mg/kg total RNA | |                      |                                  | In mice: 40% or 67% base editing |
|                 |                                  |                      |       | 1            | 1.5 mg/kg total RNA | |                      |                                  | In cynomolgus monkeys: 28% base editing, 26% reduction in serum PCSK9 |
|                 |                                  |                      |       | 2            | 1.5 mg/kg total RNA | |                      |                                  | In cynomolgus monkeys: 24% base editing, 39% reduction in serum PCSK9 |
Table 4. Cont.

| Reference       | Delivered Cargo                      | Targeted Tissue/Gene     | Route | No. of Doses | Dose       | LNP Formulation | Lipid Molar Ratios | Lipid:RNA (or DNA) Ratio (w:w) | Results                                      |
|-----------------|--------------------------------------|--------------------------|-------|--------------|------------|-----------------|-------------------|-------------------------------|---------------------------------------------|
| Liu 2019 [22]   | Cas9 mRNA + gRNA                     | Liver, Kidney, PCSK9     | IV    | 1            | 0.6 mg/kg  | Cas9 mRNA       | 16 (w)            | 15:1                          | Reduction of serum PCSK9 by 80%            |
| Prakash 2013 [114] | ASO                                   | Liver, PTEN              | IV    | 1            | 4.5 mg/kg  | DLin-KC2-DMA    | 57.5 (w)          | 10:1                          | In mice: around 85% of reduction of PTEN mRNA |
| Prakash 2013 [114] | ss-siRNA                              | Liver, PTEN              | IV    | 1            | 4.5 mg/kg  | Cholesterol     | 31.5 (w)          | 10:1                          | In mice: around 75% of reduction of PTEN mRNA |
| Prakash 2013 [114] | siRNA                                 | Liver, PTEN              | IV    | 1            | 4.5 mg/kg  | DMG-PEG         | 3.5 (w)           | 10:1                          | In mice: around 75% of reduction of PTEN mRNA |

5A2-SC8 = C₃₅H₇₃N₃O₂₅S₅; ABE = adenine base editor; ALK = anaplastic lymphoma kinase gene; C12-200 = 1,1′-[[2-[4-[[2-[bis[2-hydroxydodecyl]amino]ethyl][2-hydroxydodecyl]amino]ethyl]-1-piperazinyl]ethyl]iminobis-2-dodecanol; DLin-KC2-DMA = 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-1,3-dioxolane; DOPE = 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine; DOTAP = 1,2-dioleoyl-3-trimethylammonium-propane; DSPC = distearoylphosphatidylcholine; ECs = epithelial cells; FLuc = firefly luciferase; GFP = green fluorescent protein; gWAT = gonadal white adipose tissue; hFVIII = human factor VIII; IV = intravenous; iWAT = inguinal white adipose tissue; Macs = macrophages; P53 = tumor protein 53; PEG1000-C18 = 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-1000]; DMG-PEG = 1,2-dimyristoyl-rac-glycero-3-methoxy(polyethylene glycol)-2000; PTEN = phosphatase and tensin homolog; RB1 = retinoblastoma 1 gene; RNP = ribonucleoproteins; w = weight; w:w = weight:weight.
Rothgangl et al. [113] have obtained important results. They tested the efficacy of LNP-encapsulated ABE (adenine base editor), mRNA, and sgRNA_hP01, injected intravenously into C57BL/6J mice and cynomolgus monkeys. They were targeting the PCSK9 gene in the liver. They used the LNPs from the US 2016/0376224 A1 patent. Their LNPs had sizes between 67 and 71 nm. After two tail vein injections of 3 mg/kg total RNA per mouse, they obtained 67% base editing and a significant reduction in plasma PCSK9 and low-density lipoproteins (LDL). In cynomolgus monkeys, they obtained 28% base editing after one intravenous injection, which led to a 26% reduction in serum PCSK9 and a 9% reduction in serum LDL. After two injections, the base editing percentage remained unchanged, but they now observed a 39% of reduction in serum PCSK9 and a 19% reduction in serum LDL. They also studied the specificity of their LNP and concluded that it was indeed specific to the liver. Since this experiment was conducted on non-human primates, it is an important result for clinical applications.

Cheng et al. [94] developed the selective organ targeting (SORT) strategy. They found that the addition of the SORT molecule 1,2-dioleoyl-3-dimethylammonium-propane (DODAP) enhanced liver delivery. DODAP is an ionizable cationic SORT lipid with tertiary amino groups. To target the liver specifically, they found that the best LNP contained 20% DODAP. It had the following formulation: 5A2-SC8/DOPE/cholesterol/DMG-PEG/DODAP = 19.05/19.05/38.1/3.8/20 (mol/mol). The size of their LNPs was 155.1 nm. First, they intravenously injected these LNPs containing the Cas9 protein and a sgRNA targeting PTEN in a 2:1 ratio (w:w). They succeeded in editing PTEN exclusively in the liver with 13.9% gene editing. Secondly, they intravenously injected these LNPs containing the Cas9 mRNA with an sgRNA targeting PCSK9 in a 4:1 ratio (w:w). After three doses, they observed ~60% gene editing at the PCSK9 locus of liver tissue. This resulted in ~100% PCSK9 protein reduction in liver tissue and serum. They also evaluated the in vivo toxicity using a higher dose than needed. The LNPs used did not alter kidney or liver function. Serum cytokines were also not altered, and no adverse signs of injury were detected in the tissues. To check which liver cells were targeted by this LNP, they delivered Cre mRNA. Following a single injection (0.3 mg/kg), they observed that ~93% of all hepatocytes in the liver were targeted.

6. Targeting the Heart

To date, no study seems to have delivered the components of the CRISPR system efficiently and specifically to the heart by means of LNPs. However, some researchers have achieved the delivery of RNA, DNA, or ASO (Table 5). In this section, we review the study conducted by Scalzo et al. [115], which showed the most promising results.

Scalzo et al. [115] intravenously injected 0.2 µg of pDNA encapsulated in LNPs into C57BL/6 mice. They obtained a transfection efficiency greater than 60% on day 2 and greater than 80% on day 4. The treated group had GFP expression in the heart tissue that was two times higher than that of the control group. The formulation of their best LNP, named LNP4, was the following: C12-200/DOPE/cholesterol/DMG-PEG (35/56.5/6/2.5). The ionizable lipid:pDNA ratio was 10:1 (w:w). Their LNPs had a size of 114.7 nm. They also tested the safety of their formulations. After LNP treatment, they were no signs of an immune response in the heart. They also demonstrated that this LNP treatment did not affect cardiac cell function.
Table 5. LNP formulations targeting the heart in vivo.

| Reference | Delivered Cargo | Targeted Tissue/Gene | Route | No. of Doses | Dose | LNP Formulation | Lipids Molar Ratio (w:w) | Ionizable Lipid: RNA (or DNA) Ratio | Results |
|-----------|----------------|----------------------|-------|--------------|------|----------------|----------------------------|-------------------------------|---------|
| Scalzo 2022 [115] | pDNA | Cardiac cells | IV | 0.2 µg of pDNA | C12-200 | 35 | DOPE | 56.5 | DMG-PEG | 2.5 | Transfection efficiency Day 2 = 60% Day 4 = 80% A twofold increase in GFP expression in the heart tissue compared to the control group |
| Zhang 2020 [96] | FLuc mRNA | Heart, Spleen, Lung | IV | 0.5 mg/kg | FTT7 lipids | 22.04 | DOPE | 33.06 | Cholesterol | 44.08 | DMG-PEG | 0.82 |
| Paunovska 2018 [98] | b-DNA | Heart ECs, Lung ECs | IV | 0.75 mg/kg | 104-PEI600 | 62 | Lipid=C12Epoxy | 5 | DMG-PEG | 35 |
| Paunovska 2018 [98] | b-DNA | Heart ECs and Macs | IV | 0.75 mg/kg | 102-Spermidine | 35 | Lipid=C12Epoxy | 35 | DMG-PEG | 30 |
| Paunovska 2018 [98] | b-DNA | Heart Ecs | IV | 0.75 mg/kg | 104-PEI600 | 62 | Lipid=C12Epoxy | 5 | DMG-PEG | 30 |
| Paunovska 2018 [98] | b-DNA | Heart Macs and Lungs Macs | IV | 0.75 mg/kg | 104-PEI600 | 62 | Lipid=C12Epoxy | 18 | DMG-PEG | 20 |

ASO = antisense oligonucleotide; C12-200 = 1,1′-[4-[2-[2-[bis(2-hydroxydodecyl)amino]ethyl][2-hydroxydodecyl]amino]ethyl]-1-piperazine]-ethyl]iminobis-2-dodecanol; DOPE = 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; ECs = epithelial cells; FLuc = firefly luciferase; GFP = green fluorescent protein; IV = intravenous; Macs = macrophages; DMG-PEG = 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000; w:w = weight:weight.

7. Targeting the Spleen

To date, only a few studies have delivered treatments specifically to the spleen with LNPs (Table 6). However, Cheng et al. [94] have successfully delivered the CRISPR-Cas9 components to the spleen.

Cheng et al. [94] used their SORT strategy. They found that the addition of the SORT molecule 1,2-dioleoyl-sn-glycero-3-phosphate (18PA) enhanced spleen delivery. To target the spleen specifically, they found that the best LNP contained 30% 18PA. It had the following formulation: 5A2-SC8/DOPE/cholesterol/DMG-PEG/18PA = 16.7/16.7/33.3/3.3/30 (mol/mol). They intravenously injected these LNPs containing the Cas9 protein and a sgRNA targeting PTEN in a 2:1 ratio (w:w) and observed gene editing. The size of their LNPs was 142.1 nm. To check which populations of spleen cells were targeted by this LNP, they delivered Cre mRNA. Following a single injection (0.3 mg/kg), they observed that these LNPs targeted 12% of B cells, 10% of T cells, and 20% of macrophages.

Sago et al. [99] developed a good LNP formulation to deliver the Cas9 mRNA and an sgRNA to the spleen epithelial cells. Their LNPs were composed of 7C1/DOPE/cholesterol/DMG-PEG (60/5/10/25). When delivering two doses of 2 mg total mRNA/kg of Cas9 mRNA and e-sgICAM2 (1:1 w:w), they obtained more than 20% indels.
### Table 6. LNP formulations targeting the spleen in vivo.

| Reference     | Delivered Cargo                  | Targeted Tissue/Gene | Route  | No. of Doses | Dose   | LNP Formulation | Lipids Molar Ratios | Ionizable Lipid: RNA (or DNA) Ratio (w:w) | Results |
|---------------|----------------------------------|----------------------|--------|--------------|--------|------------------|---------------------|------------------------------------------|---------|
| Cheng 2020   | Cas9 mRNA/sgRNA                 | Spleen/PTEN          | IV     | 1            | 4.0 mg/kg | 5A2-SC8          | 16.7                | 16.7 (total lipid: RNA)                 |         |
|               |                                  |                      |        |              |         | DOPE             | 16.7                |                                          |         |
|               |                                  |                      |        |              |         | Cholesterol      | 33.3                |                                          |         |
|               |                                  |                      |        |              |         | DMG-PEG          | 3.3                 |                                          |         |
|               |                                  |                      |        |              |         | 18PA             | 30                  |                                          |         |
| Zhang 2020   | FLuc mRNA                        | Spleen               | IV     | 0.5 mg/kg    |         | FTT3 lipids      | 22.04               | 33.06 (total lipid: RNA)               |         |
|               |                                  |                      |        |              |         | DOPE             | 20                  |                                          |         |
|               |                                  |                      |        |              |         | Cholesterol      | 40                  |                                          |         |
|               |                                  |                      |        |              |         | DMG-PEG           | 2                   |                                          |         |
| Paunovska 2018 | Spleen EC                      |                      | IV     |              |         | 7C1              | 50                  |                                          |         |
|               |                                  |                      |        |              |         | DSPC             | 8                   |                                          |         |
|               |                                  |                      |        |              |         | Cholesteryl Stearate | 40              |                                          |         |
|               |                                  |                      |        |              |         | DMG-PEG           | 2                   |                                          |         |
| Sago 2018    | SpCas9 mRNA and sgICAM2ab       | Spleen EC            | IV     | 2            | 2 mg/kg  | 7C1              | 60                  |                                          |         |
|               |                                  |                      |        |              |         | DOPE             | 5                   |                                          |         |
|               |                                  |                      |        |              |         | Cholesterol      | 10                  |                                          |         |
|               |                                  |                      |        |              |         | DMG-PEG           | 25                  |                                          |         |
|               | SpCas9 mRNA + e-sgICAM2          | Lung, Spleen, Kidney | IV     | 3            | 1.5 mg/kg | 7C1              | 50                  |                                          | Good for mRNA |
|               | two sgRNAs targeting ICAM2 (sgICAM2ab) |                    |        |              |         | 18:1Lyso PC      | 50                  |                                          |         |
|               |                                  |                      |        |              |         | Cholesterol      | 20                  |                                          |         |
|               |                                  |                      |        |              |         | DMG-PEG           | 23.5                |                                          |         |
|               |                                  |                      |        |              |         | DMF-PEG           | 6.5                 |                                          |         |
| Maugeri 2019 | hEPO mRNA                        | Spleen               | IV     |              | 1.5 µg per mouse | DLin-MC3-DMA | 50                  |                                          |         |
|               |                                  |                      |        |              |         | DSPC             | 10                  |                                          |         |
|               |                                  |                      |        |              |         | Cholesterol      | 38.5                |                                          |         |
|               |                                  |                      |        |              |         | DMF-PEG           | 3.1                 |                                          |         |

18PA = 1,2-dioleoyl-sn-glycero-3-phosphate; 5A2-SC8 = C90H172N5O25S5; C12-200 = 1,1′-[2-[4-[2-[2-[bis[2-hydroxydodecyl]amino]ethy][2-hydroxydodecyl]amino]ethyl]-1-piperazinyl]ethyl]lmino]bis-2-dodecanol; DLin-KC2-DMA = 2,2-dilinoleyl-1-(2-dimethylaminoethyl)-1,3-dioxolane; DOPE = 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; DSPC = distearoylphosphatidylcholine; ECs = epithelial cells; FLuc = firefly luciferase; GFP = green fluorescent protein; hEPO = human erythropoietin; ICAM = intercellular adhesion molecule 2 gene; IV = intravenous; Macs = macrophages; DMG-PEG = 1,2-dimyristoyl-rac-glycero-3-methoxy polyethylene glycol-2000; PTEN = phosphatase and tensin homolog; RNF = ribonucleoproteins; w:w = weight:weight.

8. Targeting the Bones

Many diseases can affect the bones. In most cases, they lead to disastrous consequences in the body. Glass bone disease (osteogenesis imperfecta) [117], Paget’s disease [118], and fibrous bone dysplasia [119] are just some examples. Osteoporosis is one of the most common bone diseases [120].

Few studies have attempted to target bone with LNPs [121]. Basha et al. [122] are among those who have obtained good results. They succeeded in delivering siSOST and siLuciferase via IV injections of LNPs. Their LNP formulation was the following: D-Lin-MC3-DMA/DSPC/cholesterol/DMG-PEG (50/10/38.5/1.5). Their ionizable lipid:RNA ratio was 10:1 (w:w). The size of their LNPs was 36.93 nm for siSOST particles and 37.88 nm for siLuciferase particles. They observed that about 50% of the osteocytes took up a significant amount of LNP-siRNA. SOST mRNA was also highly expressed in mouse bones. Seven days after the treatment, they observed 60% silencing relative to PBS and/or siCtrl. To support the hypothesis of the high specificity of these LNPs, they observed that SOST mRNA was minimally expressed in the kidneys, lungs, and spleen, and that only traces of SOST mRNA were found in the liver and heart.
9. Perspectives

In this review, we described the best existing formulations to target the muscles, brain, lungs, liver, heart, spleen, and bones. With the growing popularity of LNPs, more specific formulations will surely be published in the near future. The basic components of a good LNP have already been found. Now, small modifications remain to be made to increase the specificity of the delivery. Combining two improvements from two different studies will ensure that formulations can become more and more specific. Decorating LNPs with peptides is also a promising idea that can enhance specific organ targeting. Incorporating cell-membrane-derived components into LNPs is also a promising method to increase the specificity of LNPs [123]. In conclusion, this review will help researchers to select the best LNP formulations for future experiments.

Funding: This research was funded by the Canadian Institute of Health Research (CIHR) (418059).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

AAV = adenovirus-associated vectors; ApoE = apolipoprotein E; ASO = antisense oligonucleotide; DMD = Duchenne’s muscular dystrophy; DMG-PEG = 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000; DOPE = 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; DOTAP = 1,2-dioleoyl-3-trimethylammonium-propane; DPPC = 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; DRG = dorsal root ganglia; DSPC = distearoylphosphatidylcholine; EV = extracellular vesicle; FXN = frataxin; IM = intramuscular; IP = intraperitoneal; IV = intravenous; LNP = lipid nanoparticle; NT-lipidoid = neurotransmitter-derived lipidoid; PEG = polyethylene glycol; RNP = ribonucleoprotein complex; SORT = selective organ targeting; TA = tibialis anterior; w:w = weight:weight.

References

1. Sudhakar, V.; Richardson, R.M. Gene Therapy for Neurodegenerative Diseases. *Neurotherapeutics* 2019, 16, 166–175. [CrossRef] [PubMed]
2. Manghwar, H.; Lindsey, K.; Zhang, X.; Jin, S. CRISPR/Cas System: Recent Advances and Future Prospects for Genome Editing. *Trends Plant Sci.* 2019, 24, 1122–11125. [CrossRef] [PubMed]
3. Karimian, A.; Azizian, K.; Parsian, H.; Rafieian, S.; Shafiei-Irannejad, V.; Kheyrollah, M.; Yousefi, M.; Majidinia, M.; Yousefi, B. CRISPR/Cas9 Technology as a Potent Molecular Tool for Gene Therapy. *J. Cell. Physiol.* 2019, 234, 12267–12277. [CrossRef] [PubMed]
4. Torres-Ruiz, R.; Rodriguez-Perales, S. CRISPR-Cas9 Technology: Applications and Human Disease Modelling. *Brief. Funct. Genom.* 2017, 16, 4–12. [CrossRef] [PubMed]
5. Kantor, A.; McClements, M.; MacLaren, R. CRISPR-Cas9 DNA Base-Editing and Prime-Editing. *Int. J. Mol. Sci.* 2020, 21, 6240. [CrossRef]
6. Anzalone, A.V.; Koblan, L.W.; Liu, D.R. Genome Editing with CRISPR–Cas Nucleases, Base Editors, Transposases and Prime Editors. *Nat. Biotechnol.* 2020, 38, 824–844. [CrossRef]
7. Lei, S.; Zhang, X.; Li, J.; Gao, Y.; Wu, J.; Duan, X.; Men, K. Current Progress in Messenger RNA-Based Gene Therapy. *J. Biomed. Nanotechnol.* 2020, 16, 1018–1044. [CrossRef]
8. Colella, P.; Ronzitti, G.; Mingozzi, F. Emerging Issues in AAV-Mediated In Vivo Gene Therapy. * Mol. Ther. Methods Clin. Dev.* 2018, 8, 87–104. [CrossRef]
9. Li, C.; Samulski, R.J. Engineering Adeno-Associated Virus Vectors for Gene Therapy. *Nat. Rev. Genet.* 2020, 21, 255–272. [CrossRef]
10. Naso, M.F.; Tomkowicz, B.; Perry, W.L.; Strohl, W.R. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy. *BioDrugs* 2017, 31, 317–334. [CrossRef]
11. Wu, P.; Zhang, B.; Ocansey, D.K.W.; Xu, W.; Qian, H. Extracellular Vesicles: A Bright Star of Nanomedicine. *Biomaterials* 2021, 269, 120467. [CrossRef] [PubMed]
12. Villata, S.; Canta, M.; Cauda, V. EVs and Bioengineering: From Cellular Products to Engineered Nanomachines. Int. J. Mol. Sci. 2020, 21, 6048. [CrossRef] [PubMed]

13. Samaridou, E.; Heyes, J.; Lutwyche, P. Lipid Nanoparticles for Nucleic Acid Delivery: Current Perspectives. Adv. Drug Deliv. Rev. 2020, 154–155, 37–63. [CrossRef] [PubMed]

14. Swingle, K.L.; Hamilton, A.G.; Mitchell, M.J. Lipid Nanoparticle-Mediated Delivery of MRNA Therapeutics and Vaccines. Trends Mol. Med. 2021, 27, 616–617. [CrossRef]

15. Kulkarni, J.A.; Witzigmann, D.; Chen, S.; Cullis, P.R.; van der Meer, R. Lipid Nanoparticle Technology for Clinical Translation of SiRNA Therapeutics. Acc. Chem. Res. 2019, 52, 2435–2444. [CrossRef]

16. Wang, C.; Zhang, Y.; Dong, Y. Lipid Nanoparticle–MRNA Formulations for Therapeutic Applications. Acc. Chem. Res. 2021, 54, 4283–4293. [CrossRef]

17. Cullis, P.R.; Hope, M.J. Lipid Nanoparticle Systems for Enabling Gene Therapies. Mol. Ther. 2017, 25, 1467–1475. [CrossRef]

18. Walther, J.; Wilbie, D.; Tissingh, V.S.J.; Öktem, M.; van der Veen, H.; Lou, B.; Mastrobattista, E. Impact of Formulation Conditions on Lipid Nanoparticle Characteristics and Functional Delivery of CRISPR RNP for Gene Knock-Out and Correction. Pharmaceutics 2022, 14, 213. [CrossRef]

19. Arteta, M.Y.; Kjellman, T.; Bartesaghi, S.; Wallin, S.; Wu, X.; Kvist, A.J.; Dabkowska, A.; Szekely, N.; Radulescu, U.; Benegholtz, J.; et al. Successful Reprogramming of Cellular Protein Production through MRNA Delivered by Functionalized Lipid Nanoparticles. Proc. Natl. Acad. Sci. USA 2018, 115, E3351–E3360. [CrossRef]

20. Semple, S.C.; Leone, R.; Barbosa, C.J.; Tam, Y.K.; Lin, P.J.C. Lipid Nanoparticle Delivery Systems to Enable MRNA-Based Therapeutics. Pharmaceutics 2018, 10, 398. [CrossRef]

21. Suzuki, Y.; Ishihara, H. Difference in the Lipid Nanoparticle Technology Employed in Three Approved SiRNA (Patisiran) and MRNA (COVID-19 Vaccine) Drugs. Drug. Metab. Pharmacokinet. 2021, 41, 100424. [CrossRef] [PubMed]

22. Liu, J.; Chang, J.; Jiang, Y.; Meng, X.; Sun, T.; Mao, L.; Xu, Q.; Wang, M. Fast and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles. Adv. Mater. 2019, 31, 1902575. [CrossRef] [PubMed]

23. Mendell, J.R.; Al-Zaidy, S.A.; Rodino-Klapac, L.R.; Goodspeed, K.; Gray, S.J.; Kay, C.N.; Boye, S.L.; Boye, S.E.; George, L.A.; Salabari, S.; et al. Current Clinical Applications of In Vivo Gene Therapy with AAVs. Mol. Ther. 2021, 29, 464–488. [CrossRef] [PubMed]

24. Kazemian, P.; Yu, S.Y.; Thomson, S.B.; Birkenshaw, A.; Leavitt, B.R.; Ross, C.J.D. Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components. Mol. Pharm. 2022, 19, 1669–1686. [CrossRef] [PubMed]

25. Blömer, U.; Ganser, A.; Scherr, M. Invasive Drug Delivery. In Molecular and Cellular Biology of Neuroprotection in the CNS; Springer: Berlin/Heidelberg, Germany, 2003; pp. 431–451.

26. Fenton, O.S.; Kauffman, K.J.; McClellan, R.L.; Appel, E.A.; Dorkin, J.R.; Tibbitt, M.W.; Heartlein, M.W.; DeRosa, F.; Langer, R.; Anderson, D.C. Bioinspired Alkenyl Amino Alcohol Ionizable Lipid Materials for Highly Potent In Vivo MRNA Delivery. Adv. Mater. 2016, 28, 2939–2943. [CrossRef]

27. Mitchell, M.J.; Billingsley, M.M.; Haley, R.M.; Wechsler, M.E.; Peppas, N.A.; Langer, R. Engineering Precision Nanoparticles for Drug Delivery. Nat. Rev. Drug Discov. 2020, 20, 101–124. [CrossRef]

28. Kon, E.; Elia, U.; Peer, D. Principles for Designing an Optimal MRNA Lipid Nanoparticle Vaccine. Curr. Opin. Biotechnol. 2022, 73, 329–336. [CrossRef]

29. Hou, X.; Zaks, T.; Langer, R.; Dong, Y. Lipid Nanoparticles for MRNA Delivery. Nat. Rev. Mater. 2021, 6, 1078–1094. [CrossRef]

30. Behr, M.; Zhou, J.; Xu, B.; Zhang, H. In Vivo Delivery of CRISPR-Cas9 Therapeutics: Progress and Challenges. Acta Pharm. Sin. B 2021, 11, 2150–2171. [CrossRef]

31. Han, X.; Zhang, H.; Butowska, K.; Swingle, K.L.; Alameh, M.-G.; Weissman, D.; Mitchell, M.J. An Ionizable Lipid Toolbox for RNA Delivery. Nat. Commun. 2021, 12, 7233. [CrossRef]

32. Schlich, M.; Palomba, R.; Costabile, G.; Mizrahy, S.; Panuzzo, M.; Peer, D.; Decuzzi, P. Cytosolic Delivery of Nucleic Acids: The Case of Ionizable Lipid Nanoparticles. Bioeng. Transl. Med. 2021, 6, e10123. [CrossRef] [PubMed]

33. Kulkarni, J.A.; Witzigmann, D.; Leung, J.; Tam, Y.C.; Cullis, P.R. On the Role of Helper Lipids in Lipid Nanoparticle Formulations of SiRNA. Nanoscale 2019, 11, 21733–21739. [CrossRef]

34. Cheng, X.; Lee, R.J. The Role of Helper Lipids in Lipid Nanoparticle (LNPs) Designed for Oligonucleotide Delivery. Adv. Drug Deliv. Rev. 2016, 99, 129–137. [CrossRef] [PubMed]

35. Sui, J.S.; Xu, Q.; Kim, N.; Hanes, J.; Ensign, L.M. PEGylation as a Strategy for Improving Nanoparticle-Based Drug and Gene Delivery. Adv. Drug Deliv. Rev. 2016, 99, 28–51. [CrossRef] [PubMed]

36. Nunes, S.S.; Fernandes, R.S.; Cavalante, C.H.; da Costa César, I.; Leite, E.A.; Lopes, S.C.A.; Ferretti, A.; Rubello, D.; Townsend, D.M.; de Oliveira, M.C.; et al. Influence of PEG Coating on the Biodistribution and Tumor Accumulation of PH-Sensitive Liposomes. Drug Deliv. Transl. Res. 2019, 9, 123–130. [CrossRef]

37. Menon, I.; Zaroudi, M.; Zhang, Y.; Aisenbrey, E.; Hui, L. Fabrication of Active Targeting Lipid Nanoparticles: Challenges and Perspectives. Mater. Today Adv. 2022, 16, 100299. [CrossRef]

38. DMG-PEG 2000 Powder 99 (TLC) Avanti Polar Lipids. Available online: https://www.sigmaaldrich.com/CA/en/product/avant ip polar lipids/tlc053 (accessed on 18 August 2022)

39. TCL053 (CAS Number: 2361162-70-9) | Cayman Chemical. Available online: https://www.caymanchem.com/product/37045/tcl053 (accessed on 18 August 2022)
40. 18:1 PA Avanti CAS No.108392-02-5. Available online: https://www.sigmaaldrich.com/CA/en/product/avanti/840875p (accessed on 18 August 2022).
41. DOTMA Powder Cationic Lipid Avanti Polar Lipids. Available online: https://www.sigmaaldrich.com/CA/en/product/avanti/890889?gclid=Cj0KCQjwxveXbhDDARIsAlOQx7b2VnmS_XNJi_eSu2V9q7i4B5v7ZrIecZyczWR2rqXyn9CitAWSTV70aAg vQEAiLw_wcb (accessed on 18 August 2022).
42. 9A1P9 (CAS Number: 2760467-57-8) | Cayman Chemical. Available online: https://www.caymanchem.com/product/37276/hel ping-make-research-possible (accessed on 18 August 2022).
43. YSK05 (CAS Number: 1318793-78-0) | Cayman Chemical. Available online: https://www.caymanchem.com/product/35786/hel ping-make-research-possible (accessed on 18 August 2022).
44. D-Lin-MC3-DMA | SiRNA Delivery Vehicle | MedChemExpress. Available online: https://www.medchemexpress.com/D-Lin -MC3-DMA&gclid=Cj0KCQjwxveXBhDDARIsAlOQx3ERWC1tASBjJxntT5HS1xAen-1r8x8-wjKlbEW3gBjv9C2nmQWH-UaApzaEALw_wcb (accessed on 18 August 2022).
45. NTI-O14B (CAS Number: 2739805-64-0) | Cayman Chemical. Available online: https://www.caymanchem.com/product/37095 /nti-o14b (accessed on 18 August 2022).
46. PEG Lipid | BroadPharm. Available online: https://broadpharm.com/product-categories/lipid/peg-lipid?utm_source=google&utm_medium=CPC&utm_campaign=France&utm_term=HY-112251&utm_content=D-Lin-MC3-DMA&gclid=Cj0KCQjwxveXBhDDARIsAlOQx3ERWC1tASBjJxntT5HS1xAen-1r8x8-wjKlbEW3gBjv9C2nmQWH-UaApzaEALw_wcb (accessed on 18 August 2022).
47. 306-O12B-3 | Cayman Chemical. Available online: https://www.caymanchem.com/product/37096/306-o12b-3 (accessed on 18 August 2022).
48. D-Lin-KC2-DMA (KC2, CAS Number: 1190197-97-7) | Cayman Chemical. Available online: https://www.caymanchem.com/product/43463/dlin-kc2-dma (accessed on 18 August 2022).
49. DLin-KC2-DMA | 5/1/4004 | BroadPharm. Available online: https://broadpharm.com/product/bp-25709?gclid=Cj0KCQjwxveXbhDDARIsAlOQx7b2VnmS_XNJi_eSu2V9q7i4B5v7ZrIecZyczWR2rqXyn9CitAWSTV70aAg vQEAiLw_wcb (accessed on 18 August 2022).
50. 18:1 TAP (DOTAP) | Avanti Chloroform, Powder Chloride Salt. Available online: https://avantilipids.com/product/890898p?gclid=Cj0KCQjwxveXBhDDARIsAlOQx3ERWC1tASBjJxntT5HS1xAen-1r8x8-wjKlbEW3gBjv9C2nmQWH-UaApzaEALw_wcb (accessed on 18 August 2022).
51. DOPE | 5/1/4004 | BroadPharm. Available online: https://broadpharm.com/product/bp-25709?gclid=Cj0KCQjwxveXbhDDARIsAlOQx3ERWC1tASBjJxntT5HS1xAen-1r8x8-wjKlbEW3gBjv9C2nmQWH-UaApzaEALw_wcb (accessed on 18 August 2022).
52. 5A2-SC8 | MedChemExpress. Available online: https://www.medchemexpress.com/5a2-sc8.html (accessed on 18 August 2022).
53. Cholesterol SigmaGrade, =99 57-88-5. Available online: https://www.sigmaaldrich.com/CA/en/product/sigma/c8667 (accessed on 18 August 2022).
54. 16:0 PC (DPPC). Available online: https://avantilipids.com/product/850355 (accessed on 18 August 2022).
55. Stephenson, A.A.; Flanigan, K.M. Gene Editing and Modulation for Duchenne Muscular Dystrophy. In Progress in Molecular Biology and Translational Science; Elsevier: Amsterdam, The Netherlands, 2021; Volume 182, pp. 225–255. ISBN 9780323853019.
56. Fortunato, F.; Farnì, A. The DMD Gene and Therapeutic Approaches to Restore Dystrophin. Neuromusc. Disord. 2021, 31, 1013–1020. [CrossRef] [PubMed]
57. Gutiérrez Gutiérrez, G.; Díaz-Manera, J.; Almendrote, M.; Azriel, S.; Eulalio Bárbara, J.; Cabezudo García, P.; Camacho Salas, A.; Casanova Rodriguez, C.; Cobo, A.M.; Díaz Guardiola, P.; et al. Guía Clínica Para El Diagnóstico y Seguimiento de La Distrofia Miotónica Tipo I, DM1 o Enfermedad de Steinert. Pfl. Arch. Orthopaed. Traumatol. Surg. Res. 2020, 467–480. [CrossRef]
58. Mary, P.; Servais, L.; Vialle, R. Neuromuscular Diseases: Diagnosis and Management. Orthop. Traumatol. Surg. Res. 2018, 104, S89–S95. [CrossRef]
67. Guimaraes, P.P.G.; Zhang, R.; Spektor, R.; Tan, M.; Chung, A.; Billingsley, M.M.; El-Mayta, R.; Riley, R.S.; Wang, L.; Wilson, J.M.; et al. Ionizable Lipid Nanoparticles Encapsulating Barcoded mRNA for Accelerated in Vivo Delivery Screening. J. Control. Release 2019, 316, 404–417. [CrossRef] [PubMed]

68. Dahlman, J.E.; Kaufman, K.J.; Xing, Y.; Shaw, T.E.; Mir, F.F.; Diott, C.C.; Langer, R.; Anderson, D.G.; Wang, E.T. Barcoded Nanoparticles for High Throughput in Vivo Discovery of Targeted Therapeutics. Proc. Natl. Acad. Sci. USA 2017, 114, 2060–2065. [CrossRef] [PubMed]

69. Ferlini, A.; Sabatelli, P.; Fabris, M.; Bassi, E.; Falzarano, S.; Vattemi, G.; Perrone, D.; Gualandi, F.; Maraldi, N.M.; Merlini, L.; et al. Dystrophin Restoration in Skeletal, Heart and Skin Arrector Pili Smooth Muscle of Mdx Mice by ZM2 NP-AON Complexes. Gene Ther. 2010, 17, 432–438. [CrossRef]

70. Van Haute, D.; Berlin, J.M. Challenges in Realizing Selectivity for Nanoparticle Biodistribution and Clearance: Lessons from Gold Nanoparticles. Ther. Deliv. 2017, 8, 763–774. [CrossRef]

71. Horodecka, K.; Düchler, M. CRISPR/Cas9: Principle, Applications, and Delivery through Extracellular Vesicles. Int. J. Mol. Sci. 2021, 22, 6072. [CrossRef]

72. Wang, L.; Zheng, W.; Liu, S.; Li, B.; Jiang, X. Delivery of CRISPR/Cas9 by Novel Strategies for Gene Therapy. ChemBioChem 2018, 20, 634–643. [CrossRef]

73. Xu, C.-F.; Chen, G.-J.; Luo, Y.-L.; Zhang, Y.; Zhao, G.; Lu, Z.-D.; Czarna, A.; Gu, Z.; Wang, J. Rational Designs of in Vivo CRISPR-Cas Delivery Systems. Adv. Drug Deliv. Rev. 2021, 168, 3–29. [CrossRef] [PubMed]

74. Li, L.; Hu, S.; Chen, X. Non-Viral Delivery Systems for CRISPR/Cas9-Based Genome Editing: Challenges and Opportunities. Biomaterials 2018, 171, 207–218. [CrossRef] [PubMed]

75. Moult, R.; Ray, M.; Lee, Y.-W.; Scaletti, F.; Rotello, V.M. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges. Bioconjug. Chem. 2017, 28, 880–884. [CrossRef] [PubMed]

76. Latitanzi, A.; Meneghini, V.; Pavan, G.; Amor, F.; Ramadier, S.; Felix, T.; Antoniani, C.; Masson, C.; Alibeu, O.; Lee, C.; et al. Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genetic Rearrangements. Mol. Ther. 2019, 27, 137–150. [CrossRef] [PubMed]

77. Liang, X.; Potter, J.; Kumar, S.; Zhou, Y.; Quinlanilla, R.; Sridharan, M.; Carte, J.; Chen, W.; Roark, N.; Ranganathan, S.; et al. Rapid and Highly Efficient Mammalian Cell Engineering via Cas9 Protein Transfection. J. Biotechnol. 2015, 208, 44–53. [CrossRef]

78. Ramakrishna, S.; Kwaku Dad, A.-B.; Cucullo, L. A Blood–Brain Barrier Overview on Structure, Function, Impairment, and Biomarkers of Integrity. Fluids Barriers CNS 2020, 17, 69. [CrossRef]

79. Thorley, E.M.; Iyer, R.G.; Wicks, P.; Curran, C.; Gandhi, S.K.; Abler, V.; Anderson, K.E.; Carlozzi, N.E. Understanding How Chorea Affects Health-Related Quality of Life in Huntington Disease: An Online Survey of Patients and Caregivers in the United States. J. Neurol. Phys. Med. 2018, 634–643. [CrossRef] [PubMed]

80. Gerring, Z.F.; Gamazon, E.R.; White, A.; Derks, E.M. Integrative Network-Based Analysis Reveals Gene Networks and Novel Drug Repositioning Candidates for Alzheimer Disease. Neurol. Genet. 2020, 6, e622. [CrossRef] [PubMed]

81. Thorley, E.M.; Iyer, R.G.; Wicks, P.; Curran, C.; Gandhi, S.K.; Abler, V.; Anderson, K.E.; Carlozzi, N.E. Understanding How Chorea Affects Health-Related Quality of Life in Huntington Disease: An Online Survey of Patients and Caregivers in the United States. J. Neurol. Phys. Med. 2018, 634–643. [CrossRef] [PubMed]

82. Li, L.; Hu, S.; Chen, X. Non-Viral Delivery Systems for CRISPR/Cas9-Based Genome Editing: Challenges and Opportunities. Biomaterials 2018, 171, 207–218. [CrossRef] [PubMed]

83. Zhao, M.; Liu, Y.; Ding, G.; Qu, D.; Qu, H. Online Database for Brain Cancer-Implicated Genes: Exploring the Subtype-Specific Mechanisms of Brain Cancer. BMC Genom. 2021, 22, 458. [CrossRef]

84. Li, J.; Zheng, M.; Shimoni, O.; Banks, W.A.; Bush, A.I.; Gamble, J.R.; Shi, B. Development of Novel Therapeutics Targeting the Blood–Brain Barrier: From Barrier to Carrier. Adv. Sci. 2021, 8, 2101090. [CrossRef] [PubMed]

85. Dunton, A.D.; Göpel, T.; Ho, D.H.; Burggren, W. Form and Function of the Vertebrate and Invertebrate Blood–Brain Barriers. Front. Mol. Sci. 2021, 8, 12111. [CrossRef]

86. Kadry, H.; Noorani, B.; Cucullo, L. A Blood–Brain Barrier Overview on Structure, Function, Impairment, and Biomarkers of Integrity. Fluids Barriers CNS 2020, 17, 69. [CrossRef]

87. Gernert, M.; Feja, M. Bypassing the Blood–Brain Barrier: Direct Intracranial Drug Delivery in Epilepsies. Pharmaceutics 2020, 12, 1134. [CrossRef]

88. Ma, F.; Yang, L.; Sun, Z.; Chen, J.; Rui, X.; Glass, Z.; Xu, Q. Neurotransmitter-Derived Lipidoids (NT-Lipidoids) for Enhanced Brain Delivery through Intravenous Injection. Sci. Adv. 2022, 6, eabb4429. [CrossRef] [PubMed]

89. Nabhan, J.F.; Wood, K.M.; Raito, V.P.; Morin, J.; Bhamidipaty, S.; Labranche, T.P.; Gooch, R.L.; Bulawa, C.E.; Guild, B.C. Intrathecal Delivery of Frataxin MRNA Encapsulated in Lipid Nanoparticles to Dorsal Root Ganglia as a Potential Therapeutic for Friedreich’s Ataxia. Sci. Rep. 2016, 6, 20019. [CrossRef]

90. Tamaru, M.; Akiha, H.; Nakatani, T.; Kajimoto, K.; Sato, Y.; Hatakeyama, H.; Harashima, H. Application of Apolipoprotein E-Modified Liposomal Nanoparticles as a Carrier for Delivering DNA and Nucleic Acid in the Brain. Int. J. Nanomed. 2014, 9, 4267–4276. [CrossRef]

91. Bell, S.C.; Mall, M.A.; Gutierrez, H.; Macek, M.; Madge, S.; Davies, J.C.; Burgel, P.-R.; Tullis, E.; Castaños, C.; Castellani, C.; et al. The Future of Cystic Fibrosis Care: A Global Perspective. Lancet Respir. Med. 2020, 8, 65–124. [CrossRef]

92. Cooney, A.; McCray, P.; Sinn, P. Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward. Genes 2018, 9, 538. [CrossRef] [PubMed]
93. Lebrett, M.B.; Crosbie, E.J.; Smith, M.J.; Woodward, E.R.; Evans, D.G.; Crossbie, P.A.J. Targeting Lung Cancer Screening to Individuals at Greatest Risk: The Role of Genetic Factors. *J. Med. Genet.* 2021, 58, 217–226. [CrossRef]

94. Cheng, Q.; Wei, T.; Farbiak, L.; Johnson, L.T.; Dilliard, S.A.; Siegwart, D.J. Selective Organ Targeting (SORT) Nanoparticles for Tissue-Specific MRNA Delivery and CRISPR–Cas Gene Editing. *Nat. Nanotechnol.* 2020, 15, 313–320. [CrossRef]

95. Robinson, E.; MacDonald, K.D.; Slaughter, K.; McKinney, M.; Patel, S.; Sun, C.; Sahay, G. Lipid Nanoparticle-Delivered Chemically Modified MRNA Restores Chloride Secretion in Cystic Fibrosis. *Mol. Ther.* 2018, 26, 2034–2046. [CrossRef] [PubMed]

96. Zhang, X.; Zhao, W.; Nguyen, G.N.; Zhang, C.; Zeng, C.; Yan, J.; Du, S.; Hou, X.; Li, W.; Jiang, J.; et al. Functionalized Lipid-like Nanoparticles for in Vivo MRNA Delivery and Base Editing. *Sci. Adv.* 2020, 6, 34. [CrossRef]

97. Paunovska, K.; Gil, C.J.; Lokugamage, M.P.; Sago, C.D.; Sato, M.; Lando, G.N.; Gamboa Castro, M.; Byskin, A.V.; Dahlman, J.E. Analyzing 2000 in Vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery. *ACS Nano* 2018, 12, 8341–8349. [CrossRef]

98. Paunovska, K.; Sago, C.D.; Monaco, C.M.; Hudson, W.H.; Castro, M.G.; Rudolz, T.G.; Kalathoor, S.; Vanover, D.A.; Santangelo, P.J.; Ahmed, R.; et al. A Direct Comparison of in Vitro and in Vivo Nucleic Acid Delivery Mediated by Hundreds of Nanoparticles Reveals a Weak Correlation. *Nano Lett.* 2018, 18, 2148–2157. [CrossRef]

99. Sago, C.D.; Lokugamage, M.P.; Paunovska, K.; Vanover, D.A.; Monaco, C.M.; Shah, N.N.; Castro, M.G.; Anderson, S.E.; Rudolz, T.G.; Lando, G.N.; et al. High-Throughput in Vivo Screen of Functional MRNA Delivery Identifies Nanoparticles for Endothelial Cell Gene Editing. *Proc. Natl. Acad. Sci. USA* 2018, 115, E9944–E9952. [CrossRef]

100. Qiu, M.; Tang, Y.; Chen, J.; Muriph, R.; Ye, Z.; Huang, C.; Evans, J.; Henske, E.P.; Xu, Q. Lung-Selective MRNA Delivery of Synthetic Lipid Nanoparticles for the Treatment of Pulmonary Lymphangioleiomyomatosis. *Proc. Natl. Acad. Sci. USA* 2022, 119, e2116271119. [CrossRef]

101. Liu, S.; Cheng, Q.; Wei, T.; Yu, X.; Johnson, L.T.; Farbiak, L.; Siegwart, D.J. Membrane-Destabilizing Ionizable Phospholipids for Organ-Selective MRNA Delivery and CRISPR–Cas Gene Editing. *Nat. Mater.* 2021, 20, 701–710. [CrossRef] [PubMed]

102. Hagino, Y.; Khalil, I.A.; Kimura, S.; Kusumoto, K.; Harashima, H. GALA-Modified Lipid Nanoparticles for the Targeted Delivery of Plasmid DNA to the Lungs. *Mol. Pharm.* 2018, 15, 878–888. [CrossRef] [PubMed]

103. Kusumoto, K.; Akita, H.; Ishitsuka, T.; Matsumoto, Y.; Nomoto, T.; Furukawa, R.; El-Sayed, A.; Hatakeyama, H.; Kajimoto, K.; Yamada, Y.; et al. Lipid Envelope-Type Nanoparticle Incorporating a Multifunctional Peptide for Systemic siRNA Delivery to the Pulmonary Endothelium. *ACS Nano* 2020, 7, 7534–7542. [CrossRef] [PubMed]

104. van Ginkel, W.G.; Rodenburg, I.L.; Harding, C.O.; Hollak, C.E.M.; Heiner-Fokkema, M.R.; van Spronsen, F.J. Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1. *Pediatr. Drugs* 2019, 21, 413–426. [CrossRef] [PubMed]

105. Chinsky, J.M.; Singh, R.; Ficicioglu, C.; van Karnebeek, C.D.M.; Grompe, M.; Mitchell, G.; Waisbren, S.E.; Gucsavas-Calikoglu, M.; Wasserstein, M.P.; Coakley, K.; et al. Diagnosis and Treatment of Tyrosinemia Type 1: A US and Canadian Consensus Group Review and Recommendations. *Genet. Med.* 2017, 19, 1380–1395. [CrossRef]

106. Czaja, A.J. Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions. *Gut Liver* 2016, 10, 177. [CrossRef]

107. Akinc, A.; Maier, M.A.; Manoharan, M.; Fitzgerald, K.; Jayaraman, M.; Barros, S.; Ansell, S.; Du, X.; Madden, T.D.; et al. The Onpattro Story and the Clinical Translation of Nanomedicines Containing Nucleic Acid-Based Drugs. *Nat. Nanotechnol.* 2019, 14, 1084–1087. [CrossRef]

108. Akinc, A.; Querbes, W.; De, S.; Qin, J.; Frank-Kamenetsky, M.; Jayaprakash, K.N.; Jayaraman, M.; Rajeev, K.G.; Cantley, W.L.; Dorkin, J.R.; et al. Targeted Delivery of RNAi Therapeutics with Endogenous and Exogenous Ligand-Based Mechanisms. *Mol. Ther.* 2010, 18, 1357–1364. [CrossRef]

109. Quiviger, M.; Giannakopoulous, A.; Verhennes, S.; Marie, C.; Stavrou, E.F.; Vanhoorelbeke, K.; Izsák, Z.; de Meyer, S.F.; Athanassiadou, A.; Scherman, D. Improved Molecular Platform for the Gene Therapy of Rare Diseases by Liver Protein Secretion. *Eur. J. Med. Genet.* 2018, 61, 723–728. [CrossRef]

110. Yonezawa, S.; Koide, H.; Asai, T. Recent Advances in siRNA Delivery Mediated by Lipid-Based Nanoparticles. *Adv. Drug Deliv. Rev.* 2020, 154–155, 64–78. [CrossRef]

111. Cui, L.; Hunter, M.R.; Sonzini, S.; Pereira, S.; Romanelli, S.M.; Liu, K.; Li, W.; Liang, L.; Yang, B.; Mahmoudi, N.; et al. Mechanistic Studies of an Automated Lipid Nanoparticle Reveal Critical Pharmaceutical Properties Associated with Enhanced MRNA Functional Delivery In Vitro and In Vivo. *Small* 2022, 18, 2105832. [CrossRef]

112. Cui, L.; Pereira, S.; Sonzini, S.; van Pelt, S.; Romanelli, S.M.; Liang, L.; Ulkoski, D.; Krishnamurthy, V.R.; Brannigan, E.; Brankin, C.; et al. Development of a High-Throughput Platform for Screening Lipid Nanoparticles for MRNA Delivery. *Nanoscale* 2022, 14, 1480–1491. [CrossRef]

113. Rothgangl, T.; Dennis, M.K.; Lin, P.J.C.; Oka, R.; Witzigmann, D.; Villiger, L.; Qi, W.; Hruzova, M.; Kissling, L.; Lenggenhager, D.; et al. In Vivo Adenine Base Editing of PCSK9 in Macaques Reduces LDL Cholesterol Levels. *Nat. Biotechnol.* 2021, 39, 949–957. [CrossRef] [PubMed]

114. Prakash, T.P.; Lima, W.F.; Murray, H.M.; Elbashir, S.; Cantley, W.; Foster, D.; Jayaraman, M.; Chappell, A.E.; Manoharan, M.; Swayze, E.E.; et al. Lipid Nanoparticles Improve Activity of Single-Stranded siRNA and Gapmer Antisense Oligonucleotides in Animals. *ACS Chem. Biol.* 2013, 8, 1402–1406. [CrossRef] [PubMed]
115. Scalzo, S.; Santos, A.K.; Ferreira, H.A.; Costa, P.A.; Prazeres, P.H.; da Silva, N.J.; Guimarães, L.C.; de Silva, M.M.; Rodrigues Alves, M.T.; Viana, C.T.; et al. Ionizable Lipid Nanoparticle-Mediated Delivery of Plasmid DNA in Cardiomyocytes. *Int. J. Nanomed.* 2022, 17, 2865–2881. [CrossRef] [PubMed]

116. Maugeri, M.; Nawaz, M.; Papadimitriou, A.; Angerfors, A.; Camponeschi, A.; Na, M.; Hölttä, M.; Skantzze, P.; Johansson, S.; Sundqvist, M.; et al. Linkage between Endosomal Escape of LNP-MRNA and Loading into EVs for Transport to Other Cells. *Nat. Commun.* 2019, 10, 4333. [CrossRef] [PubMed]

117. Rossi, V.; Lee, B.; Marom, R. Osteogenesis Imperfecta: Advancements in Genetics and Treatment. *Curr. Opin. Pediatr.* 2019, 31, 708–715. [CrossRef] [PubMed]

118. Appelman-Dijkstra, N.M.; Papapoulos, S.E. Paget’s Disease of Bone. *Best Pract. Res. Clin. Endocrinol. Metab.* 2018, 32, 657–668. [CrossRef]

119. Chapurlat, R.D.; Meunier, P.J. Fibrous Dysplasia of Bone. *Best Pract. Res. Clin. Rheumatol.* 2000, 14, 385–398. [CrossRef]

120. Srivastava, M.; Deal, C. Osteoporosis in Elderly: Prevention and Treatment. *Clin. Geriatr. Med.* 2002, 18, 529–555. [CrossRef]

121. Chindamo, G.; Sapino, S.; Peira, E.; Chirio, D.; Gonzalez, M.C.; Gallarate, M. Bone Diseases: Current Approach and Future Perspectives in Drug Delivery Systems for Bone Targeted Therapeutics. *Nanomaterials* 2020, 10, 875. [CrossRef]

122. Basha, G.; Ordebad, M.; Scott, W.R.; Cottle, A.; Liu, Y.; Wang, H.; Cullis, P.R. Lipid Nanoparticle Delivery of siRNA to Osteocytes Leads to Effective Silencing of SOST and Inhibition of Sclerostin in Vivo. *Mol. Ther. Nucleic Acids* 2016, 5, e363. [CrossRef]

123. Kularatne, R.N.; Crist, R.M.; Stern, S.T. The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery. *Pharmaceutica* 2022, 15, 897. [CrossRef] [PubMed]